Company profile: Phagenesis
1.1 - Company Overview
Company description
- Provider of neurostimulation solutions for dysphagia treatment, developing the Phagenyx System, which delivers Pharyngeal Electrical Stimulation to restore neurological control of swallowing. The system tailors stimulation to patient sensory capacity and uses a dual-function catheter for feeding and electrical therapy, harnessing neuroplasticity to improve safe swallowing in patients, including those post-stroke or with neuro-deficit diseases.
Products and services
- Patient-Tailored Stimulation: A patient-specific configuration within the Phagenyx System that customizes electrical stimulation levels based on individual sensory capacity to optimize dysphagia therapy efficacy
- Phagenyx System: A PES-driven neurostimulation device that restores neurological control of swallowing in dysphagia, harnessing neuroplasticity to relearn lost function often accompanying stroke or other neuro-deficit diseases
- Pharyngeal Electrical Stimulation (PES): An electrical-stimulation-based therapy delivered by the Phagenyx System to improve swallowing function in dysphagia patients by harnessing neuroplasticity through pharyngeal stimulation
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Phagenesis
Protagenic Therapeutics
HQ: United States
Website
- Description: Provider of biotechnology solutions developing naturally occurring human brain hormones to treat anxiety- and depression-based mood disorders. Offers PT00114, a synthetic analog of the neuropeptide TCAP that regulates stress response for depression, PTSD, anxiety, and addiction, and the TCAP R&D platform to address neuropsychiatric and neurodegenerative diseases at the cellular level in the brain.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Protagenic Therapeutics company profile →
CerSci Therapeutics
HQ: United States
Website
- Description: Provider of non-opioid medicines for acute and chronic pain, developing CT-044 with FDA-approved IND to proceed to Phase I safety and tolerability clinical trials; a non-opioid drug development firm based in Dallas, Texas.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CerSci Therapeutics company profile →
Jazz Pharmaceuticals
HQ: United States
Website
- Description: Provider of specialty pharmaceuticals for underserved neurology and psychiatry markets. Includes Xyrem and Xywav for cataplexy and excessive daytime sleepiness in narcolepsy; Epidiolex for seizures in Lennox-Gastaut syndrome, Dravet syndrome, or Tuberous Sclerosis Complex; Vyxeos for acute myeloid leukemia; Zepzelca for metastatic small cell lung cancer; Defitelio for hepatic veno-occlusive disease.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Jazz Pharmaceuticals company profile →
Onward
HQ: The Netherlands
Website
- Description: Provider of an implantable neuro-stimulation system (INS) with real-time motion feedback and training tools to rehabilitate patients with neurological disorders, including spinal cord injury (SCI).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Onward company profile →
T3D Therapeutics
HQ: United States
Website
- Description: Provider of remedial therapeutics for Alzheimer's disease and other CNS disorders, including T3D-959, an investigational oral drug candidate designed to treat Alzheimer's by improving brain glucose and lipid metabolism, potentially addressing multiple disease manifestations.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full T3D Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Phagenesis
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Phagenesis
2.2 - Growth funds investing in similar companies to Phagenesis
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Phagenesis
4.2 - Public trading comparable groups for Phagenesis
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →